Cargando…

Risk stratification in emergency patients by copeptin

BACKGROUND: Rapid risk stratification is a core task in emergency medicine. Identifying patients at high and low risk shortly after admission could help clinical decision-making regarding treatment, level of observation, allocation of resources and post discharge follow-up. The purpose of the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Iversen, Kasper, Gøtze, Jens P, Dalsgaard, Morten, Nielsen, Henrik, Boesgaard, Søren, Bay, Morten, Kirk, Vibeke, Nielsen, Olav W, Køber, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053286/
https://www.ncbi.nlm.nih.gov/pubmed/24884642
http://dx.doi.org/10.1186/1741-7015-12-80
_version_ 1782320349472358400
author Iversen, Kasper
Gøtze, Jens P
Dalsgaard, Morten
Nielsen, Henrik
Boesgaard, Søren
Bay, Morten
Kirk, Vibeke
Nielsen, Olav W
Køber, Lars
author_facet Iversen, Kasper
Gøtze, Jens P
Dalsgaard, Morten
Nielsen, Henrik
Boesgaard, Søren
Bay, Morten
Kirk, Vibeke
Nielsen, Olav W
Køber, Lars
author_sort Iversen, Kasper
collection PubMed
description BACKGROUND: Rapid risk stratification is a core task in emergency medicine. Identifying patients at high and low risk shortly after admission could help clinical decision-making regarding treatment, level of observation, allocation of resources and post discharge follow-up. The purpose of the present study was to determine short-, mid- and long-term mortality by plasma measurement of copeptin in unselected admitted patients. METHOD: Consecutive patients >40-years-old admitted to an inner-city hospital were included. Within the first 24 hours after admission, a structured medical interview was conducted and self-reported medical history was recorded. All patients underwent a clinical examination, an echocardiographic evaluation and collection of blood for later measurement of risk markers. RESULTS: Plasma for copeptin measurement was available from 1,320 patients (average age 70.5 years, 59.4% women). Median follow-up time was 11.5 years (range 11.0 to 12.0 years). Copeptin was elevated (that is, above the 97.5 percentile in healthy individuals). Mortality within the first week was 2.7% (17/627) for patients with elevated copeptin (above the 97.5 percentile, that is, >11.3 pmol/L) compared to 0.1% (1/693) for patients with normal copeptin concentrations (that is, ≤11.3 pmol/L) (P <0.01). Three-month mortality was 14.5% (91/627) for patients with elevated copeptin compared to 3.2% (22/693) for patients with normal copeptin. Similar figures for one-year mortality and for the entire observation period were 27.6% (173/627) versus 8.7% (60/693) and 82.9% (520/527) versus 57.5% (398/693) (P <0.01 for both), respectively. Using multivariable Cox regression analyses shows that elevated copeptin was significantly and independently related to short-, mid- and long-term mortality. Adjusted hazard ratios were 2.4 for three-month mortality, 1.9 for one-year mortality and 1.4 for mortality in the entire observation period. CONCLUSIONS: In patients admitted to an inner-city hospital, copeptin was strongly associated with short-, mid- and long-term mortality. The results suggest that rapid copeptin measurement could be a useful tool for both disposition in an emergency department and for mid- and long-term risk assessment.
format Online
Article
Text
id pubmed-4053286
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40532862014-06-12 Risk stratification in emergency patients by copeptin Iversen, Kasper Gøtze, Jens P Dalsgaard, Morten Nielsen, Henrik Boesgaard, Søren Bay, Morten Kirk, Vibeke Nielsen, Olav W Køber, Lars BMC Med Research Article BACKGROUND: Rapid risk stratification is a core task in emergency medicine. Identifying patients at high and low risk shortly after admission could help clinical decision-making regarding treatment, level of observation, allocation of resources and post discharge follow-up. The purpose of the present study was to determine short-, mid- and long-term mortality by plasma measurement of copeptin in unselected admitted patients. METHOD: Consecutive patients >40-years-old admitted to an inner-city hospital were included. Within the first 24 hours after admission, a structured medical interview was conducted and self-reported medical history was recorded. All patients underwent a clinical examination, an echocardiographic evaluation and collection of blood for later measurement of risk markers. RESULTS: Plasma for copeptin measurement was available from 1,320 patients (average age 70.5 years, 59.4% women). Median follow-up time was 11.5 years (range 11.0 to 12.0 years). Copeptin was elevated (that is, above the 97.5 percentile in healthy individuals). Mortality within the first week was 2.7% (17/627) for patients with elevated copeptin (above the 97.5 percentile, that is, >11.3 pmol/L) compared to 0.1% (1/693) for patients with normal copeptin concentrations (that is, ≤11.3 pmol/L) (P <0.01). Three-month mortality was 14.5% (91/627) for patients with elevated copeptin compared to 3.2% (22/693) for patients with normal copeptin. Similar figures for one-year mortality and for the entire observation period were 27.6% (173/627) versus 8.7% (60/693) and 82.9% (520/527) versus 57.5% (398/693) (P <0.01 for both), respectively. Using multivariable Cox regression analyses shows that elevated copeptin was significantly and independently related to short-, mid- and long-term mortality. Adjusted hazard ratios were 2.4 for three-month mortality, 1.9 for one-year mortality and 1.4 for mortality in the entire observation period. CONCLUSIONS: In patients admitted to an inner-city hospital, copeptin was strongly associated with short-, mid- and long-term mortality. The results suggest that rapid copeptin measurement could be a useful tool for both disposition in an emergency department and for mid- and long-term risk assessment. BioMed Central 2014-05-16 /pmc/articles/PMC4053286/ /pubmed/24884642 http://dx.doi.org/10.1186/1741-7015-12-80 Text en Copyright © 2014 Iversen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Iversen, Kasper
Gøtze, Jens P
Dalsgaard, Morten
Nielsen, Henrik
Boesgaard, Søren
Bay, Morten
Kirk, Vibeke
Nielsen, Olav W
Køber, Lars
Risk stratification in emergency patients by copeptin
title Risk stratification in emergency patients by copeptin
title_full Risk stratification in emergency patients by copeptin
title_fullStr Risk stratification in emergency patients by copeptin
title_full_unstemmed Risk stratification in emergency patients by copeptin
title_short Risk stratification in emergency patients by copeptin
title_sort risk stratification in emergency patients by copeptin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053286/
https://www.ncbi.nlm.nih.gov/pubmed/24884642
http://dx.doi.org/10.1186/1741-7015-12-80
work_keys_str_mv AT iversenkasper riskstratificationinemergencypatientsbycopeptin
AT gøtzejensp riskstratificationinemergencypatientsbycopeptin
AT dalsgaardmorten riskstratificationinemergencypatientsbycopeptin
AT nielsenhenrik riskstratificationinemergencypatientsbycopeptin
AT boesgaardsøren riskstratificationinemergencypatientsbycopeptin
AT baymorten riskstratificationinemergencypatientsbycopeptin
AT kirkvibeke riskstratificationinemergencypatientsbycopeptin
AT nielsenolavw riskstratificationinemergencypatientsbycopeptin
AT køberlars riskstratificationinemergencypatientsbycopeptin